BRCA1 and BRCA2 germline mutations driven signaling pathway alterations are sufficient to initiate breast tumorigenesis by the PIK3CA <sup>H1047R</sup> oncogene
Poornima Bhat‐Nakshatri(Indiana University School of Medicine), Harikrishna Nakshatri(Richard L. Roudebush VA Medical Center), Katie Batic(Indiana University School of Medicine), Christopher Herodotou(Indiana University School of Medicine), Anna Maria Storniolo(Indiana University Health), Hongyu Gao(Indiana University School of Medicine), Patrick C. McGuire(Indiana University School of Medicine), Henry Mang(Indiana University School of Medicine), George E. Sandusky(Indiana University – Purdue University Indianapolis), Duojiao Chen(Indiana University School of Medicine), Xiaoling Xuei(Indiana University Health), Yunlong Liu(Harbin Engineering University), Aditi S. Khatpe(Indiana University Health)
Cited by 1
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis
|Breast Cancer Research|2006|987
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
|Journal of Biological Chemistry|2001|968
Biogeography of the ecosystems of the healthy human body
|Genome biology|2013|686